linjc16/ctgov huggingface dataset:
Prevalence of Microcirculatory Alterations in Intensive Care Patients

Study Overview
=================
Brief Summary
-----------------
Recent research has focused on the investigation of sublingual microcirculatory alterations in different patient categories, like cardiac surgery and sepsis. The microcirculation plays a pivotal role in tissue oxygenation and can be non invasively visualized by sidestream dark field (SDF) imaging. The objective is to carry out a international multi center study to investigate the prevalence of microcirculatory alterations in intensive care patients. Up to the present time, a comprehensive prevalence study like this has not been carried out.

Detailed Description
-----------------
Visualization of the sublingual microcirculation at a fixed time point with SDF- or OPS-imaging in all adult patients of participating intensive care units, regardless of their underlying disease. Concurrently, data on both patient characteristics (e.g. severity of illness, treatment) and ICU characteristics will be obtained.

Official Title
-----------------
Observation of the Prevalence of Sublingual Microcirculatory Alterations With SDF Imaging in Intensive Care Patients

Conditions
-----------------
Critical Illness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 18 informed consent Exclusion Criteria: injury to the maxillofacial area recent maxillofacial injury

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| intensive care patients<br>no interventions | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| microcirculatory alterations related to underlying illness, expressed as - amongst others- microvascular flow index (MFI), proportion of perfused vessels (PPV). |  | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| microcirculatory alterations related to: hospital/intensive care length of stay mortality severity of illness |  | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
microcirculatory alterations, SDF imaging
Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections

Study Overview
=================
Brief Summary
-----------------
Purpose of the study: The overall goal of this study is to better understand patient experience with injectable facial fillers so that the investigators may provide the best results for their patients. To do this, the investigators are administering surveys to approximately 50 patients who have been treated by Dr. Anthony P Sclafani, MD, FACS. Participation: Participants will be asked to complete a brief questionnaire regarding their most recent treatment by Dr. Sclafani with a facial injectable filler. All responses will be analyzed anonymously.

Detailed Description
-----------------
Patients previously treated by the PI with dermal fillers will be mailed questionnaires about their experience with the treatment. These questionnaires will be deidentified prior to recording answers on a computer based spreadsheet.

Official Title
-----------------
Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections

Conditions
-----------------
Rhytids, Wrinkles

Intervention / Treatment
-----------------
* Device: hyaluronic acid or calcium hydroxylapatite filler


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated by Principal Investigator with facial soft tissue filler within the past 2 years willing to complete the research survey. Exclusion Criteria: Any patient not treated by Principal Investigator with facial soft tissue filler within the past 2 years.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Facial Soft Tissue Filler Patients<br>Patients previously treated by Principal Investigator with facial soft tissue fillers within the past 2 years | Device: hyaluronic acid or calcium hydroxylapatite filler<br>* Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.<br>* Other names: Radiesse;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfaction with treatment with facial soft tissue fillers |  | 0-24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Social and behavioral effects of facial soft tissue filler treatment |  | 0-24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Soft tissue filler, Dermal filler, Complications, Patient satisfaction
Extraperitoneal Versus Transperitoneal Cesarean Section

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare post operative morbidity between extra peritoneal cesarian and trans peritoneal cesarean section.

Official Title
-----------------
Extraperitoneal Versus Transperitoneal Cesarean Section: A Prospective Randomized Comparison

Conditions
-----------------
Cesarean, Extraperitoneal

Intervention / Treatment
-----------------
* Procedure: Extraperitoneal Cesarean
* Procedure: Transperitoneal Cesarean


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective cesarean (primary or repeated up to four) Exclusion Criteria: emergent cesarean macrosomia (fetal weight > 4500 g) history of major abdominal surgery suspected abnormal placentation placenta previa

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Transperitoneal Cesarean<br> | Procedure: Transperitoneal Cesarean<br>* Pfannenstiel-Kerr technique for laparatomy and uterine entry<br>|
| Active Comparator: Extraperitoneal Cesarean<br> | Procedure: Extraperitoneal Cesarean<br>* Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| post operative pain | Perceived pain scores will be measured by an visual analog scale. | One hour before cesarean and 24 hour postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| delivery time | skin incision to delivery | 2 minutes after delivery | 
| operation time | skin incision to skin closure | 5 minutes postoperatively | 
| hemoglobin differences |  | one hour before cesarean, 48 hour postoperatively | 
| need for extra analgesic |  | 48 hour | 
| nausea |  | 48 hour | 
| vomiting |  | 48 hour | 
| thoracic and shoulder pain |  | 48 hour | 
| Urogenital distress measured by Urogenital Distress Inventory |  | One hour before cesarean and 24 hour postoperatively | 
| Oral intake | The percentage of patients who tolerates oral intake. Oral intake will be allowed 4-6 hour after cesarean for extraperitoneal group. For intraperitoneal group it will be allowed when patient passed gas. | 48 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cesarean, extraperitoneal, Cesarean, Pain
Vitamin A Therapy for Tuberculosis

Study Overview
=================
Brief Summary
-----------------
The study will determine whether a daily vitamin and mineral supplement (a multivitamin including Vitamin A) will improve health when added to standard chemotherapy for tuberculosis. This study will compare the effectiveness of the multivitamin in HIV infected and HIV uninfected patients.

Detailed Description
-----------------
By the year 2000, 13.8 % of individuals with HIV will be co-infected with tuberculosis (TB). Despite effective TB chemotherapy, mortality rates remain extremely high, and no simple, inexpensive intervention is available. Prior to the discovery of antibiotic treatment, cod-liver oil, a potent source of Vitamin A, was the standard treatment for TB. Vitamin A is essential for normal immune function, and Vitamin A supplementation is used in many countries to reduce mortality in children. Vitamin A deficiency in HIV infected people has been associated with increased mortality in the United States, Haiti, Malawi, and Uganda. This study will determine whether daily Vitamin A supplementation, given concurrently with TB chemotherapy, will reduce mortality in adults with HIV and TB. All study participants will receive standard TB chemotherapy (isoniazid, rifampicin, streptomycin, pyrazinamide) for the first 2 months, followed by isoniazid and ethambutol for the following 6 months. Participants will be randomized to receive either a daily vitamin and mineral supplement or placebo. Participants will be followed for 24 months after study enrollment.

Official Title
-----------------
Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS

Conditions
-----------------
Pulmonary Tuberculosis, HIV Infections

Intervention / Treatment
-----------------
* Drug: multivitamin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sputum-confirmed pulmonary tuberculosis Resident of Zomba or Blantyre Districts, Malawi Willing to take tuberculosis chemotherapy as recommended by the National Tuberculosis Control Programme Exclusion Criteria: Prior treatment for tuberculosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: multivitamin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morbidity |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vitamin A
The Effect of Rectus Sheath Block on the Postoperative Analgesia in the Patients Undergoing Robotic Single Port Cholecystectomy

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to investigate the effect of rectus sheath block on abdominal pain score after robotic single port cholecystectomy. The secondary purpose of this study is to investigate the effect of rectus sheath block on fentanyl consumption during stay of recovery room after surgery.

Conditions
-----------------
Gallbladder Diseases

Intervention / Treatment
-----------------
* Drug: denogan and rectus sheath block
* Drug: denogan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: robotic single Port cholecystectomy for gallbladder disease Exclusion Criteria: Allergy to ropivacaine, infection, history of abdominal surgery, body mass index more than 30

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Rectus sheath block group<br>administration of denogan rectus sheath block with 0.375% ropivacaine | Drug: denogan and rectus sheath block<br>* administration of denogan and rectus sheath block with 0.375% ropivacaine<br>|
| Placebo Comparator: Control group<br>just administration of denogan | Drug: denogan<br>* administration of denogan<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Abdominal pain score after surgery |  | Change from baseline abdominal pain score up to 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fentanyl consumption in recovery room |  | Up to 1 hours |
Effect of Normal Aging on Language Processing

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to understand the effect of age on language abilities. The investigators aim at investigating the cerebral modifications that take place in normal aging, at the functional an anatomical level.

Official Title
-----------------
Cognitive Mechanisms and Cerebral Substrate of Naming Impairment During Aging. Behavior and Neuroimaging Approaches.

Conditions
-----------------
Cognition

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age of 30 years and above Right handed French native speakers Affiliation to French social security (Sécurité Sociale) Medical interview Consent form signed Exclusion Criteria: Cerebral or respiratory pathologies Any MRI contrindication

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy adults<br>20 young adults aged between 30 and 50 years old. 20 middle aged adults aged between 50 and 70 years old. 20 older adults of 70 years old and more. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood Oxygen Level Dependent functional MRI | We use 3 functional tasks using block paradigm: Object naming, Verbal generation and semantic judgment, to elicit BOLD response using fMRI in order to compare functional activation patterns between subjects. We also use hypercapnic challenge to elicit BOLD response in order to obtain Cerebral Vascular Reactivity properties of subjects. | There will be a unique MRI measurement for each participant. Group analyses presentation after 1 year. | 
| Anatomical MRI | We use Voxel Based Morphometry to compare cortical volume (grey matter) between subjects. We also use tractography Diffusion Tensor Imaging to compare white matter properties between subjects. | There will be a unique MRI measurement for each participant. Group analyses presentation after 1 year. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cognition
Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

Study Overview
=================
Brief Summary
-----------------
Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms of functional dyspepsia. Patients suffering from this condition have difficulties digesting food. They feel full after eating a few bites; they feel bloated and their stomachs hurt. The goal of this study is to see if itopride helps to relieve the symptoms of functional dyspepsia.

Detailed Description
-----------------
The study lasts approximately 10 weeks. Patients may either receive the real itopride, or a sugar pill called placebo. They have equal chances of receiving either treatment. After having completed this study, patients may be eligible to continue treatment for a longer period. At that point, all patients receive itopride. Patients need to come to the clinic for evaluations 4 times during the trial. Various evaluations are done at these visits, such as a physical exam, lab tests, evaluation of the heart condition, and questionnaires need to be completed by the patient to see if the drug helps them in relieving their symptoms.

Official Title
-----------------
A Multicentre, Randomized, Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Itopride HCl in Patients Suffering From Functional Dyspepsia

Conditions
-----------------
Dyspepsia

Intervention / Treatment
-----------------
* Drug: Itopride Hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients suffering from functional dyspepsia according to Rome II criteria 18-65 years old Absence of, or infrequent heartburn (one episode per week or less) Helicobacter pylori (H. pylori) negative Normal upper endoscopy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Itopride Hydrochloride|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptom relief |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of symptom relief on quality of life |  |  | 
| Safety |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Functional dyspepsia, Abdominal Symptom relief, Fullness, Bloating, Indigestion
Evaluation of the Effectiveness of Surgical Treatment of Villo-nodular Synovitis of the Hip in Children

Study Overview
=================
Brief Summary
-----------------
Villo-nodular synovitis can affect the joints, bursae or tendon sheaths. This condition is rare, with 1.8 cases per million inhabitants. The hip is affected in 3.6 to 18.1% of cases. The age of predilection is between 30 and 50 years old and this condition is rarely described in children. Two articles report a case of villous-nodular synovitis of the child's hip. Surgical treatment by resection seems to be consensus but various adjuvant treatments are also proposed. A case of villous-nodular synovitis of the hip in children was treated without surgical intervention. The main objective of this study was to evaluate the efficacy of surgical treatment of villous nodular synovitis of the hip in children.

Detailed Description
-----------------
French multicentric cases serie

Official Title
-----------------
Evaluation of the Effectiveness of Surgical Treatment of Villo-nodular Synovitis of the Hip in Children in a Retrospective Case Series

Conditions
-----------------
Synovitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children with histologically villo-nodular synovitis of the hip Surgical procedures performed for the treatment of this synovitis Exclusion Criteria: Degree of bone maturation and Risser test greater than 4 at the time of diagnosis Parents opposing the use of their child's data / Patient opposing the use of his/her data

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in the range of motion of the hip in degrees | Evaluation of extension / flexion / abduction / adduction / external rotation / internal rotation of the hip | before surgery and 4 months after surgery | 
| Incidence of signal changes in the X-Ray |  | 4 months after surgery | 
| Incidence of signal changes in the MRI |  | 4 months after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in the scale measure of patient's pain intensity |  | before surgery and 4 months after surgery | 
| Incidence of complications after surgery |  | 4 month after surgery | 
| Number of additional treatments used in addition to surgery | Frequency of adjuvant treatments | 4 month after surgery | 
| Change from baseline in the physical activity evaluated by a questionnaire | yes /no questionnaire | before surgery and 4 months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
villo-nodular synovitis, Hip, Surgery